Foundation Venture Capital Group

Visikol is a CRO focused on advanced drug discovery that is leading the field of bio-imaging, bioinformatics and image analysis. We conduct end-to-end drug discovery services that include both 2D and 3D in vitro models and assays, 3D whole mount tissue imaging, digital pathology and custom drug discovery projects. Visikol offers a portfolio of drug discovery services ranging from 2D and 3D cell culture model and assay development to in vitro screening, animal tissue histology and automated image processing. The focus of these services is to transform tissues into images and ultimately into quantitative data sets that can be mined for actionable insights that help our Clients make more informed decisions during the drug discovery process. Additionally, Visikol manufactures and sells a suite of tissue clearing reagents and 3D immuno-labeling kits. These products allow researchers to easily and rapidly image whole tissues and 3D cell culture models in 3D instead of traditional 2D sectioning. For more information about Visikol or its services, please visit our website at visikol.com.

MentiNova, Inc. is a pharmaceutical company based in Piscataway, New Jersey, established in 2012. The company focuses on developing an oral medication aimed at treating symptoms associated with Parkinson's disease, a neurodegenerative disorder. MentiNova's innovative approach seeks to enhance the quality of life for patients by providing effective treatment options for this condition and related mental health issues. Through its research and development efforts, MentiNova aims to support healthcare providers in managing the challenges posed by Parkinson's disease.

GeneAssess, Inc. is a New Jersey-based biotechnology company that is working to validate FRY, a cancer molecular signature gene discovered by GeneAssess scientists that could provide a more accurate diagnostic biomarker for cancer staging. The FRY gene appears to be found in the breast cancer model but also shows potential for other cancers. In research performed to date, mutations in the gene increase rat susceptibility to mammary cancer and FRY reduced the growth of highly aggressive human breast cancer cells in animal models. GeneAssess plans to validate FRY as a predictive biomarker for breast and other cancers, to detect genetic mutations in at-risk populations and to explore target validation for FRY. The company has an exclusive license to the intellectual property developed by Dr. Zarbl.

Snowdon Inc. is a pharmaceutical company that is focused on three major therapeutic areas with substantial market potential: acute and chronic pain, neurological disorders, and infectious diseases. These medical conditions cause immense suffering, economic hardship, and loss of life among millions of people every day. In each of these therapeutic areas, Snowdon has discovered prospective drug candidates that address the urgent need for safe and effective medicines. Snowdon’s pipeline extends from NCEs to repurposing off-patent drugs for new clinical indications. The company’s preclinical lead compound, SND-121, has shown exceptional safety and efficacy when administered orally in rodent models as a treatment for neuropathic pain. SND-121 appears to treat pain through a unique mechanism of action, distinct from traditional analgesics such as opioid narcotics, NSAIDs, or the antiepileptics gabapentin and pregabalin.